Peanut allergy is a generally persistent, sometimes life-threatening food allergy that is increasing in prevalence in Western countries. 1, 2 Several studies have investigated individual thresholds and the population threshold for allergic reactions to peanut through double-blind, placebo-controlled food challenges (DBPCFC) and shown that allergic reactions can be caused by miniscule amounts of peanut protein.
| INTRODUC TI ON
Peanut allergy is a generally persistent, sometimes life-threatening food allergy that is increasing in prevalence in Western countries. 1, 2 Several studies have investigated individual thresholds and the population threshold for allergic reactions to peanut through double-blind, placebo-controlled food challenges (DBPCFC) and shown that allergic reactions can be caused by miniscule amounts of peanut protein. [3] [4] [5] [6] Current management strategies for peanut allergy are limited to strict avoidance of peanut consumption and use of rescue medication upon symptoms due to unintentional peanut ingestion. 7, 8 However, complete avoidance of peanut is difficult due to its widespread use as a food ingredient in packaged foods and in restaurant or catering meals.
Unexpected allergic reactions to food and to peanut in particular are frequent, occur in nearly half of food-allergic patients and symptoms can be mild, moderate and severe. [9] [10] [11] [12] Packaged food products do on occasion contain unintended allergen residue despite efforts to minimize cross-contact [13] [14] [15] [16] and a recent Dutch study following allergic patients found that packaged foods were the main cause of unexpected reactions. 11 In a number of instances, food manufacturers utilize "may contain" precautionary allergen labeling (PAL) as a voluntary measure to communicate potential risk to allergic consumers. However, inconsistent application of PAL by the food industry and a disconnect between the presence or absence of PAL and the actual risk of the product have led to a loss of trust in PAL, consumption of PAL labeled products, and increased risk-taking by allergic consumers. 17, 18 Multiple studies report baseline risks of allergic reactions in peanut-allergic consumers of certain product categories to be between 1% and 3% after accounting for frequency of contamination, for both products without mention of peanut on the label, and for products containing PAL for peanut. 14, [19] [20] [21] Additionally, when researching unexpected allergic reactions, Michelsen et al 11 reported that the allergen was not mentioned as an ingredient or warning on the labels in 37% of the cases, indicating that 63% of the reactions were caused by products with the allergen of interest on the label and could be the result of increased risk-taking behavior due to frustrations with PAL.
To date there are no approved therapeutic interventions for peanut allergy or any food allergy. However, recent reviews highlight the development and potential of immunotherapy as an active form of treatment and disease-modifying therapy for peanut allergy. [22] [23] [24] Different forms of immunotherapy trials exist including oral, sublingual or epicutaneous and all have an efficacy endpoint of an increased individual threshold (eliciting dose) or the cumulative reactive dose tested during DBPCFC. Desensitization results for peanut have shown good efficacy for increasing an individual's threshold with a good safety profile but the ability of immunotherapy to induce long-term tolerance needs further study. [22] [23] [24] It has been demonstrated that a history of more severe reactions due to accidental allergen exposure or lower tolerated doses during food challenge was indicative of a significantly lower QOL in children. 25 Thus, an increase in threshold following immunotherapy in a foodallergic individual who initially had a low threshold can have a significant impact on that food-allergic individual's quality of life, as well as their caretakers.
A recent study by Baumert et al 26 aimed to quantitatively demonstrate the clinical benefits of increasing an individual's threshold through immunotherapy in the American population.
A >95% reduction in reaction risk was demonstrated, across packaged food categories, for the peanut-allergic individual who achieved a threshold of 300 mg peanut protein or more after immunotherapy. It was concluded that an increase in an individual threshold from 100 mg or less to 300 mg peanut protein or more is a clinically meaningful endpoint and a relevant objective for peanut immunotherapy. 26 Increasing one's individual threshold to 300 mg peanut protein or higher could have a significant impact on the number of unexpected allergic reactions from consumption of packaged foods contaminated with peanut as prior DBPCFC research has indicated that without immunotherapy, >65% of the peanut-allergic population would be predicted to experience an allergic reaction when exposed to 300 mg peanut protein. 7 Further, >80% of the peanut-allergic population would be predicted to experience an allergic reaction when exposed to 1000 mg peanut protein. 7 In this study, we applied quantitative (probabilistic) risk modeling using food consumption data from the 2007-2010 Dutch National Food Consumption Survey (DNFCS) and the EFSA Comprehensive European Food Consumption Database to determine the clinical relevance of increasing an individual's threshold through immunotherapy in a European population. We report and quantify the probability of an allergic reaction for given thresholds due to the unintended presence of peanut protein in packaged food products, as well as the protective nature and reduction of risk due to increasing one's individual threshold through immunotherapy. It is not the focus or intention of our study to examine the safety or efficacy of immunotherapy treatments and future research could be directed to assess the risk reduction by specific immunotherapy treatments through the application of data from recent and ongoing clinical trials.
| ME THODS

| Input parameters for quantitative risk assessment
The overall quantitative risk assessments performed in this study incorporated a wide range of input variables in order to predict the risk of an allergic reaction after exposure to residual peanut protein in packaged food products. The three primary inputs for the risk assessment were the peanut-allergic individual's clinical threshold value, the concentration of peanut protein in the consumed food product, and the amount of food consumed per eating occasion of selected packaged food products. The overall study design and simulation methods for studying quantitative risk reduction through immunotherapy in a food-allergic population were detailed previously by Baumert et al 26 for the US population and are briefly described below as adapted for the current study.
| Peanut-allergic individual clinical threshold amounts
A series of individual quantitative risk assessments were conducted through utilization of a constant individual clinical threshold of 1, 
| Concentration
The concentration of unintended peanut protein found in packaged food products for this study was selected randomly from the semi- 
| Consumption data for product categories
Dutch consumption data were obtained from the Dutch National
Food Consumption Survey (DNFCS) of the National Institute of Public Health and the Environment. The food products found within the 2007-2010 DNFCS database have been labeled with the common European Food Safety Authority (EFSA) food codes for consumption surveys (FoodEx2), 34 and five food groups were used in the current project (cookies, croissants, doughnuts, ice cream, salty snacks). Detailed food codes and categories for this study can be found in Tables S1-S5 .
Consumption of two age-groups was studied separately, children (7-11 years) and adolescents-adults ( 
| Quantitative risk assessment
As previously described by Baumert et al 26 the Monte Carlo-based risk model simulated 100 000 eating occasions through a random selection and calculation of exposure doses compared with a constant threshold dose of 1, 3, 10, 30, 100, 300, or 1000 mg of peanut protein to determine whether there was a risk of an allergic reaction.
The risk model calculated a mg exposure amount of peanut protein through a random selection of the concentration of peanut residue (1, 3, 10, 30, 100, 300, and 1000 ppm of peanut protein) and pairing this with a randomly selected consumption value from the reported consumed amounts per eating occasion in the DNFCS for each product category. An allergic reaction was predicted to occur if the exposure dose (mg of peanut protein) was greater than the individual threshold dose (mg of peanut protein). This process of simulating 100 000 eating occasions was then repeated 50 times for a total of 5 000 000 simulated eating occasions for each individual threshold value across two age-groups, children (7-11 years) and adolescentsadults (12-69 years). The overall approach of this study is outlined in Figure 1 .
The results of this study are presented as the peanut-allergic individual risk or the probability of a reaction occurring when it is conservatively assumed that all individuals are peanut-allergic and all consume a product that contains unintended peanut residue during every eating occasion. In previous studies, this was presented as the peanut-allergic user risk. 13, 19, 32 It is well understood that peanut-allergic individuals are not likely to consume of the selected product categories during every eating occasion, and thus, the risks in everyday life would be lower than those presented in this study. However, these overconservative estimations do allow for the calculation of predicted decrease in risk when consuming a contaminated packaged food product due to an increased threshold of reaction following peanut immunotherapy.
| Risk reduction calculation
The reduction in risk of a predicted allergic reaction due to an increased threshold of reaction following immunotherapy can be expressed as a percentage decrease in risk to further examine the benefits of an increased threshold. The percentage decrease in risk was calculated using the percentage of predicted reactions and using the following formula:
| RE SULTS
In order to quantify the risk reduction in a European population consuming packaged foods due to an increased threshold of reaction following immunotherapy, we first had to assess the risk of five packaged food product categories (cookies, croissants, doughnuts, ice cream, salty snacks) using consumption data from the DNFCS.
The summary statistics (mean, 90th percentile, 95th percentile, maximum) for consumption per eating occasion are presented in Table 1 for children (7-11 years) and adolescents-adults (12-69 years) for each product category. Ice cream was the highest consumed product on a population basis for both children and adolescents-adults.
Unsurprisingly, across all product categories, the maximum amount consumed in a single eating occasion was higher for adolescentsadults than for children. The average amount consumed was higher in the adolescents-adult population in all product categories except for cookies. Simulated consumption summary statistics from risk assessments performed in this study can be found in Table S6 and closely match the sampled consumptions from Table 1 .
The percentage of eating occasions predicted to result in an allergic reaction for each of the selected products and agegroups is presented in Table 2 . As expected from the consumption results, adolescents-adults are predicted to have a slightly higher risk compared to children with a similar peanut protein threshold value for all of the product categories except for cookies, where children have the slightly higher risk. Croissants were included in the current study due to a prestudy assumption of a possible low number of consumer of doughnut in a European population. However, doughnuts or similar products were reported as consumed frequently enough in the Dutch population to continue with further risk assessments. The consumption distributions of croissants and doughnut within the DNFCS dataset were similar (Table 1) and thus led to a similar number of predicted allergic reactions (Table 2) , although the maximum consumption of doughnuts is higher and leads to a slightly higher predicted risk than croissants in individuals with a 100 mg peanut protein threshold. product or the general physiological limitations regarding the size of a human stomach. Similarly, an individual with a 300 mg peanut protein threshold would need to consume 300 g or more of a product containing 1000 ppm peanut protein to exceed their threshold dose, an instance which was only reported to occur for adolescents-adults consuming ice cream based on the DNFCS survey data. Thus, a reaction was only predicted to occur if the maximum consumer of ice cream was peanut-allergic and the ice cream contained a worst-case concentration of peanut.
The reduction in risk of a predicted allergic reaction due to an increased threshold of reaction following immunotherapy can be expressed as a percentage decrease in risk to further examine the benefits of an increased threshold. The percentage decrease in risk was calculated using the percentage of predicted reactions in Table 2 .
For example, an adult consumer of cookies with a baseline threshold of 1 mg peanut protein pre-immunotherapy that increases their threshold to 100 mg post-immunotherapy decreases their risk of allergic reaction from 48.2% to 0.21% (Table 2) , which corresponds to a decrease in risk 99.6%.
Adult consumers of cookies that increased their threshold to 300 or 1000 mg peanut protein were not predicted to have an allergic reaction and had a decrease in risk of >99.99% within our study. Further calculations of the decrease in risk are presented in Table 3 for children and adolescents-adults consuming cookies or ice cream, two of the respective food product categories with the highest and lowest risk reduction percentages. Decrease in risk calculations is presented for all product and age combinations in Figure S1 .
As shown in Table 3 , children who reach a post-immunotherapy individual threshold value of 100 mg peanut protein experienced a risk reduction of 90.0%-99.3% (>99.99% risk reduction for from salty snack consumption due to no predicted risk in the current simulation), while comparable adolescents-adults experienced a risk reduction of 78.9%-99.6% depending on their pre-immunotherapy threshold value and product being consumed. In the current simulation, individuals who achieved a post-immunotherapy individual threshold value of 300 mg peanut protein or more were no longer predicted to be at risk of an allergic reaction due to unintentional peanut protein in the selected packaged foods for all age and product combinations (>99.99% risk reduction), except one. In this case, adolescents-adults who reached an ED of 300 mg 
These food product categories were selected as examples with the highest and lowest risk reduction percentages, dependent on the age-group. Decrease in risk calculations is presented for all product and age combinations in Figure S1 [Colour figure can be viewed at wileyonlinelibrary.com]
| D ISCUSS I ON
The desire to avoid potential life-threatening symptoms due to unintentional, accidental ingestion of allergens in the "uncontrolled" environment of everyday life is the main motivation of peanut-allergic individuals to be enrolled in an immunotherapy study. 36 Therefore, the results of immunotherapy trials should be analyzed with these thoughts in mind.
Baumert et al 26 were the first to quantify the level of protection inferred by a clear increase in threshold during peanut immunotherapy against allergic reactions to food products that contain trace amounts of peanut. The work of Baumert et al 26 focused on the US population, and the current study is the first to quantify the level of protection provided by peanut immunotherapy in a European population. Methods of the current study were designed in a similar fashion to Baumert et al 26 with the intention of comparing previous results to the level of protection inferred in a European population.
Accordingly, food categories were chosen for the current study to match US food categories previously analyzed and results of the two studies were similar on a number of levels. Even though Baumert et al 26 did not split consumption into separate age-groups, the reported consumption trends between the USA and the Netherlands were comparable. The average grams consumed across food categories in the US values were closer to the Dutch adult age-group than children, but both age-groups were still comparable. Average consumption in both studies was highest for ice cream followed by doughnuts/snack cakes/croissants and then cookies or salty snacks. were no longer predicted to be at risk of an allergic reaction due to unintentional peanut protein in the current study (>99.99% risk reduction), whereas similar individuals in 26 experienced a 94.9%-99.9% reduction in risk across product categories.
While much of the focus from this study could be placed on individuals being able to achieve a reduction in risk of 99% or greater, it should also be noted that children or adults with a pre-immunotherapy threshold of 1 mg peanut protein already benefit from a reduction in risk of >50% in most scenarios if they are able to reach a post-immunotherapy individual threshold of 10 mg peanut protein.
Children and adults with a pre-immunotherapy threshold of 1 or 3 mg peanut protein and who are able to achieve a post-immunotherapy threshold of 30 mg peanut protein have a predicted reduction in risk of 61.6%-88.9% depending on the product being consumed.
Finally, children who reach a post-immunotherapy individual threshold value of 100 mg peanut protein experienced a risk reduction of 90.0%->99.99% and comparable adolescents-adults experienced a risk reduction of 78.9%-99.6% depending on their pre-immunotherapy threshold value and product being consumed. So while it is clear that a reduction in risk of 99.9% is clinically relevant, a reduction in risk of 50%-85% could also already be clinically relevant for the most highly sensitive peanut-allergic individuals.
Avoidance of peanut is only an effective risk management strategy when peanut is clearly identifiable in packaged food products.
However, that is not always possible as packaged foods with and without PAL can contain similar concentrations of an unexpected allergen 13, 19 and cause allergic reactions. 11 The reduction in risk due to an increased threshold during immunotherapy provides a clear, clinically significant benefit to the allergic individual seeking to avoid a reaction due to accidental ingestion of allergens when consuming packaged foods. Still, it must be noted that our study is limited in scope to selected packaged food products and does not allow and One possible limitation of the current study is the use of a threshold value at a single point in time. Some studies have shown that individual thresholds can vary over time. [37] [38] [39] Additionally, extrinsic factors such as exercise, sleep deprivation, alcohol, and food matrix during consumption could influence the occurrence of an allergic reaction. 40 Based on available data, it is known that individual heterogeneity exists as to an increase or decrease in threshold at the repeated DBPCFC, but the average threshold across the population increases or at least remains steady over time. 37 We acknowledge that an individual threshold may vary slightly over time, but the DBPCFC is the gold standard for food allergy diagnosis and primary outcome of food allergen immunotherapy is to measure the degree of desensitization, or the change in the threshold by a food challenge, preferably a DBPCFC. 41 Thus, we have remained consistent with clinical recommendations for our current analysis.
It is important to also discuss the results of this study in a 
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